Antivascular and antitumor evaluation of 2-amino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4H-chromenes, a novel series of anticancer agents

Shire BioChem, Inc., Laval, Quebec, Canada.
Molecular Cancer Therapeutics (Impact Factor: 5.68). 12/2004; 3(11):1375-84.
Source: PubMed


A novel series of 2-amino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4H-chromenes was identified as potent apoptosis inducers through a cell-based high throughput screening assay. Six compounds from this series, MX-58151, MX-58276, MX-76747, MX-116214, MX-116407, and MX-126303, were further profiled and shown to have potent in vitro cytotoxic activity toward proliferating cells only and to interact with tubulin at the colchicine-binding site, thereby inhibiting tubulin polymerization and leading to cell cycle arrest and apoptosis. Furthermore, these compounds were shown to disrupt newly formed capillary tubes in vitro at low nanomolar concentrations. These data suggested that the compounds might have vascular targeting activity. In this study, we have evaluated the ability of these compounds to disrupt tumor vasculature and to induce tumor necrosis. We investigated the pharmacokinetic and toxicity profiles of all six compounds and examined their ability to induce tumor necrosis. We next examined the antitumor efficacy of a subset of compounds in three different human solid tumor xenografts. In the human lung tumor xenograft (Calu-6), MX-116407 was highly active, producing tumor regressions in all 10 animals. Moreover, MX-116407 significantly enhanced the antitumor activity of cisplatin, resulting in 40% tumor-free animals at time of sacrifice. Our results identify MX-116407 as the lead candidate and strongly support its continued development as a novel anticancer agent for human use.

Download full-text


Available from: Sui Xiong Cai, May 22, 2014
  • Source
    • "Among different types of chromene systems, 2-amino-4H- chromenes are of particular utility as they belong to privileged medicinal scaffolds serving for generation of small-molecule ligands with highly pronounced anticoagulant-, diuretic-, spasmolitic-and antianaphylactic activities [7] [8] [9] [10] [11] [12]. The current interest in 2-amino-4H- chromene derivatives arises from their potential application in the treatment of human inflammatory TNFα-mediated diseases, such as psoriatic arthritis and rheumatoid and in cancer therapy [13] [14] [15]. Many of the methods reported for the synthesis of these compounds [16] [17] [18] [19] [20] are associated with the use of hazardous organic solvents, long reaction time, use of toxic amine-based catalysts, and lack of general applicability. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A simple, efficient, and environmentally benign method has been developed for the synthesis of 2-amino-4H-chromenes under the heterogeneous catalysis of nanocrystalline magnesium oxide in aqueous media in excellent yields at room temperature. This method provides a green and improved pathway for the synthesis of chromenes in the terms of excellent yields, short reaction times and reusability catalyst.
    Full-text · Article · Jan 2013
  • [Show abstract] [Hide abstract]
    ABSTRACT: We have identified 5-(3-chlorothiophen-2-yl)-3-(4-trifluoromethylphenyl)-1,2,4-oxadiazole (1d) as a novel apoptosis inducer through our caspase- and cell-based high-throughput screening assay. Compound 1d has good activity against several breast and colorectal cancer cell lines but is inactive against several other cancer cell lines. In a flow cytometry assay, treatment of T47D cells with 1d resulted in arrest of cells in the G(1) phase, followed by induction of apoptosis. SAR studies of 1d showed that the 3-phenyl group can be replaced by a pyridyl group, and a substituted five-member ring in the 5-position is important for activity. 5-(3-Chlorothiophen-2-yl)-3-(5-chloropyridin-2-yl)-1,2,4-oxadiazole (4l) has been found to have in vivo activity in a MX-1 tumor model. Using a photoaffinity agent, the molecular target has been identified as TIP47, an IGF II receptor binding protein. Therefore, our cell-based chemical genetics approach for the discovery of apoptosis inducers can identify potential anticancer agents as well as their molecular targets.
    No preview · Article · Sep 2005 · Journal of Medicinal Chemistry
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Two new acetylpyridinehydrazones derived from cyanoacetic acid hydrazide have been synthesized namely: cyanoacetic acid (1-pyridin-3 or 4-yl-ethylidene) hydrazides (1a,b). and some derived ring systems: 2-imino or 2-oxo-2H-chromenes (2a,b and 3a,b), substituted 2-thioxo-2,3-dihydrothiazoles (4a-d), substituted 2-thioxo-2,3-dihydro-6H-thiazolo[4,5-d]pyrimidin-7-ones (5a-d), substituted dihydrothiazoles (7a,b), and substituted 2-oxo-1,2-dihydropyridines (8a-d and 9a,b). Fifteen compounds were evaluated for their anticancer activity using the USA-NCI in-vitro screening program. Among the tested compounds, 8d exhibited a high value of percent tumor growth inhibition at concentrations of 10(-5) to 10(-7) M in all cancer cell lines, while 8b exhibited a significant value of percent tumor growth inhibition at concentration <10(-8 )M against non-small cells lung HOP-92. In addition, nine compounds were investigated for their in-vitro effect on the replication of hepatitis-C virus (HCV) in HepG2 hepatocellular carcinoma cell line infected with the virus using the reverse transcription polymerase chain reaction technique. Six compounds were capable of inhibiting the replication of both the HCV RNA (+)- and (-)-strands at 5-100 microg/mL concentration range. The activity order was 7b > 1b = 3a > 4c > 7a > 5c.
    Full-text · Article · Jan 2006 · Archiv der Pharmazie
Show more